Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use Concurrent enrollment in another clinical study, unless in follow-up period or it is an observational study Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study; Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed Concurrent hepatic veno-occlusive disease (VOD) based on clinical examination Concurrent administration of other anti-cancer therapy during the course of this study is not allowed; note that concurrent use of supportive care medications (e.g. anti-resorptive agents, pain medications) is allowed Concurrent administration of other cancer specific therapy during the course of this study is not allowed Concurrent administration of other cancer specific therapy during the course of this study is not allowed The subject must have completed RT with concurrent TMZ at least weeks prior to the planned start of treatment on this study UNLESS there is pathological verification of recurrent tumor and at least weeks have elapsed since the end of RT with concurrent TMZ. Concurrent brain directed therapy (beyond SRS and NovoTTF-M as per protocol) Concurrent enrollment in another interventional trial Concurrent administration of other cancer specific therapy during the course of this study is not allowed Eligible for otherwise curative treatment or undergoing concurrent therapy Concurrent serious infection Concurrent treatment with any chemotherapeutic agent Patient must not have any active infection or concurrent illness obscuring toxicity or dangerously altering drug metabolism Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study. Concurrent brain-directed therapy Concurrent enrollment in another study unless it is an observational (e.g. non-interventional) study. Enrollment in a concurrent clinical study. Concurrent treatment with non-permitted drugs and other interventions. Concurrent radiation sensitizing medications concurrent with radiation, per treatment physician Concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of the study drugs Male breast cancer patients. . Patients may not be on a concurrent clinical trial, unless approved by Investigator. Concurrent participation in another clinical study that may add additional safety risks and/or confound study results* Any known concurrent RAF or PIKCA mutation Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study Concurrent treatment with any chemotherapeutic agent. Concurrent treatment with a non-permitted drug Patients may not be on a concurrent clinical trial, unless approved by PI. Concurrent treatment with any other anti-leukemia agent Prior or concurrent treatment with AR antagonists or CYP enzyme inhibitor. Concurrent treatment with a non-permitted drug Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study, is excluded Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study Concurrent enrollment in another clinical trial, unless in a follow-up period or it is an observational study Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complication of study therapy Eligible for and planning to receive standard fractionated RT with concurrent TMZ Concurrent use of systemic immune suppressive other than calcineurin inhibitors and sirolimus Concurrent enrollment in another clinical study, unless in a follow-up period or the study is an observational or non-interventional study Note: Concurrent and/or adjuvant chemotherapy does not make a patient ineligible; participation in a concurrent treatment protocol does not make a patient ineligible Concurrent treatment with another anti-estrogen Patient with any significant concurrent illness PHASE II COLORECTAL CANCER COHORT (MEDI+C ONLY):\r\nConcurrent enrollment in another clinical study, unless it is an observational non-interventional clinical study or the follow-up of an interventional study; any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable; NOTE: Local treatment of isolated lesions for palliative intent is acceptable (e.g., by local surgery or radiotherapy) Concurrent use of bosentan Concurrent administration of any other antitumor therapy. Concurrent therapy with any drug active against simplexvirus (HSV) (acyclovir, valacyclovir, penciclovir, famcyclovir, gancyclovir, foscarnet, cidofovir) The presence of a concurrent non-appendiceal metastatic cancer Patient with concurrent use of complementary or alternative medicines Concurrent serious infection See Disease Characteristics PRIOR CONCURRENT THERAPY: Previous or concurrent cancer except Concurrent NSAID therapy; washout period of days Concurrent enrollment in another clinical study Concurrent use of anticholinergics Concurrent use of phenothiazine and atypical antipsychotics Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study Prior or concurrent use of trastuzumab Any concurrent treatment that would compromise the study including but not limited to: Concurrent somatostatin analogues are allowed provided that the dose has been stable (+/- mg) for at least weeks Concurrent use of rifampin or ketoconazole Concurrent enrollment in another clinical study, except for non-interventional, observational studies Prior or concurrent use of erythropoietin is disallowed Prior or concurrent topical or localized glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted Plan to administer concurrent radiation therapy now or for progressive symptoms during treatment Concurrent therapy given to treat cancer Concurrent therapeutic intervention (including radiation therapy and NovoTTF). Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional study Concurrent treatment with a non permitted drug Concurrent spironolactone use No concurrent herbal or unconventional therapy Concurrent hormone replacement therapy Enrollment on any additional investigational agent study. Enrollment on concurrent observational study is allowed following consultation with the Sponsor. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) study. Concurrent treatment with non-permitted drugs and other interventions Concurrent or planned concurrent treatment with anticoagulants such as Coumadin or heparin, except to maintain patency of in dwelling catheters Prior or concurrent therapy with somatostatin analogs is permitted for patients with secretory NET Concurrent cancer therapy is not permitted. Concurrent use of calcineurin-inhibitors plus sirolimus; either agent alone is acceptable Participants with concurrent use of calcineurin-inhibitor plus sirolimus (either agent alone is acceptable) Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study or the follow-up period of an interventional study Concurrent treatment with any systemic chemotherapeutic agent Concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of the study drugs Concurrent neurodegenerative disease, Concurrent use of other antiandrogens, estrogen-like agents, or a-reductase inhibitors Concurrent treatment with a non-permitted drug Patients receiving any concurrent immunosuppressants Participants receiving any other cancer directed concurrent therapy; such as concurrent chemotherapy, radiotherapy, or hormonal therapy; concurrent treatment with bisphosphonates/denosumab is allowed but should be started before starting treatment on study Concurrent estrogens, anti-estrogens or progesterone compounds Treatment plan to include delivery of concurrent chemoradiotherapy Serious concurrent illness: Patients in cohort being treated with concurrent HER therapy must have undergone treatment with the concurrent HER therapy selected by their attending physician for at least weeks prior to initiation on this study Patients who are receiving any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study; concurrent treatment with bisphosphonates and denosumab is allowed for bony metastases but should be started before the first dose of neratinib Prior or concurrent exposure to approved or investigational multiple myeloma treatments (concurrent treatment with bone-protecting agents (eg, bisphosphonates, denosumab), or steroids (not exceeding mg prednisone per day or equivalent) are only allowed if given in a stable dose and for a nonmalignant condition; concurrent treatment with erythropoietin-stimulating agents (ESAs) are not allowed.) Patients must be registered on the study within weeks of completion of concurrent chemoradiation Concurrent treatment with a non-permitted drug. Concurrent enrollment in another therapeutic investigational study or have previously taken ibrutinib Subject must understand that while they are on study they cannot have any concurrent curative therapy for their cancer other than what is outlined in the protocol Concurrent enrollment in another clinical study, unless in a follow-up period or it is an observational study Concurrent neoplasia requiring cytotoxic therapy Histopathological documentation of MCC concurrent with the diagnosis of metastatic disease No concurrent cytochrome P A inducers Concurrent therapy for cancer Concurrent neoplasia requiring cytotoxic therapy Concurrent radiation therapy, except for palliation of a single painful bone lesion or fracture. Requirement for concurrent systemic glucocorticoid therapy at greater than physiologic replacement doses Concurrent serious infection Concurrent use of QT-prolonging medication Concurrent treatment for cancer No concurrent use of statins (except for pravastatin, if absolutely necessary) Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study Concurrent anticancer treatment with any agent other than iniparib and any co-administered chemotherapeutic agent(s) specified on the parental study protocol are not permitted throughout the course of the study. Concurrent treatment with relevant doses of systemic glucocorticosteroids. Significant concurrent disease. Subjects who are considered to require concurrent therapy with another influenza antiviral medication. Have a concurrent major debilitating illness, Concurrent use of bupropion Previous or concurrent use of flibanserin Not have: concurrent use of ethyol; severe cognitive compromise; known history of central nervous system (CNS) disease (e.g. brain metastases, seizure disorder); concurrent use of amifostine, concurrent abdominal radiotherapy; concurrent use of quinolone antibiotic therapy; chronic alcoholism (as determined by the investigator); known hypersensitivity to olanzapine; known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months; history of uncontrolled diabetes mellitus (stable insulin dose and/or stable oral hypoglycemic agent permitted); or have planned chemotherapy or radiation during the days following study initiation Receiving concurrent radiation therapy Concurrent use of somatostatin Are receiving concurrent radiation therapy (RT) Concurrent liposomal doxorubicin or any other liposomal agent Concurrent breast related radiation therapy is allowed BRAIN CANCER: Status post concurrent radiation therapy and daily temozolomide Concurrent use of tamoxifen, raloxifene, or any of the aromatase inhibitors Concurrent use of the aromatase inhibitor exemestane Concurrent radiation, chemotherapeutic, or investigational therapy other than transplant related therapy Concurrent enrollment in LCCC Concurrent antiandrogen therapy allowed but not required Patients receiving concurrent additional biologic therapy Concurrent use of calcineurin-inhibitor plus sirolimus (either agent alone is acceptable) Current enrollment in any other trial that entails the concurrent administration of any other agent designed to enhance postoperative recovery Concurrent hepatic veno-occlusive disease (VOD) Concurrent diuretic use Patients with evidence of concurrent adenocarcinoma-in-situ Patients who have received a non-FDA or non-EMA approved anti-EGFR agent or any other non-FDA or non-EMA approved agent as part of concurrent radiotherapy Concurrent therapy with other seizurogenic medications. Completion of treatment with standard radiation (with or without concurrent therapy) Concurrent therapy will be allowed concurrent NSAID treatments while undergoing treatment Concurrent disease or condition that interferes with participation or safety